A little redness, a small bruise, or an itch where you injected is one of the most common things GLP-1 users notice, and it's almost always harmless. What matters is telling an ordinary reaction apart from the few signs that need a call to your prescriber.
What's typical
Mild redness, slight swelling, itching, or a small bruise at the injection site are common with weekly GLP-1 injections and usually go away on their own. For scale, the Zepbound (tirzepatide) prescribing information lists injection-site reactions in 6–8% of trial participants on the drug, against 2% on placebo (DailyMed, Zepbound label, revised 8/2026 (external link)). They tend to become less frequent as your technique improves and you rotate sites consistently.
Reports also differ between drugs. A 2026 analysis of the European EudraVigilance database found statistically significant reporting signals for injection site erythema, injection site pruritus, and injection site reaction with tirzepatide compared with semaglutide (Popa Ilie et al., Pharmaceuticals, 2026, DOI (external link)). This kind of analysis measures reporting patterns, not confirmed rates, so it can't tell you your own odds. It does suggest site reactions aren't identical across these medications.
How to reduce site reactions
The two most important habits have real evidence behind them, though it comes from insulin users, not GLP-1 trials. A 2025 meta-analysis of 51 studies in people with insulin-treated diabetes looked at what drives lipohypertrophy, the firm, fatty lumps that build up where injections are repeated. The strongest factor by far was incorrect site rotation (odds ratio 8.85, 95% CI 5.10–15.33), followed by needle reuse (3.20, 1.99–5.13), longer duration of injection therapy, and more injections per day. Both leading risk factors come down to technique (Mader et al., Journal of Diabetes Science and Technology, 2025, DOI (external link)). That study covered daily insulin injections, not weekly GLP-1s, so treat the exact numbers as a rough guide; the direction of the advice is what carries over.
- Rotate injection sites systematically. The Zepbound pen instructions, for example, say to change your injection site each week, using the abdomen or thigh yourself or the back of the upper arm if someone else injects, and to pick a different spot even within the same area (Zepbound pen Instructions for Use, revised April 2026 (external link)). This is the habit that matters most.
- Use a new needle each time. Reusing needles raises discomfort, infection risk, and lipohypertrophy risk.
- Follow your pen's instructions on temperature. They differ by product: the Zepbound pen instructions say it isn't necessary to warm the pen to room temperature before injecting.
- Avoid scar tissue, moles, and irritated skin.
- Press, don't rub. If there's a little blood afterward, press a cotton ball or gauze on the spot; the Zepbound instructions say not to rub the site.
When to call your prescriber
- Redness or swelling that's spreading, getting worse after 48 hours, or comes with warmth and increasing pain. These can be signs of infection.
- A firm lump that doesn't go away over time. It may be lipohypertrophy, and your prescriber can help you adjust your rotation. It matters beyond the lump itself, because injecting into that tissue can make absorption less predictable.
- Any sign of a broader allergic reaction, such as hives, swelling beyond the injection site, or difficulty breathing. That needs prompt medical attention, not a routine follow-up.
Study findings above are attributed to their authors and were located via PubMed.
This is general education, not medical advice. Signs of infection or a broader allergic reaction warrant prompt medical attention. Follow your prescriber's guidance and your medication's injection instructions.